Catching up with $115 million of VC money

Private biotech companies tend to make a lot of noise when their investor wire transfers clear and then promptly go back to toiling in media silence. STAT’s Kate Sheridan tracked down a few of biotech’s recent check recipients to check on how things are going.

One, Pyxis Oncology, has quickly assembled a scientific staff and hired a former Pfizer executive to be its CEO. Another, Curamir Therapeutics, has advanced its RNA-based approach to treating cancer and expects to seek permission to start its first human trial next year. A third, Oncorus, has executed on its clinical goals but run into an unexpected challenge in the form of a trademark dispute with a similarly named European firm.

Read more.